AkzoNobel et Axalta finaliseront-elles leur fusion avant le 31 décembre 2026 ?
échéance 2026-12-31
confiance moyenne
preuve niveau 2
33 %estimation Asturna
Critère de résolution
Oui si AkzoNobel et/ou Axalta annoncent, par communiqué ou dépôt auprès de la SEC, que la fusion est finalisée (la clôture a eu lieu) au plus tard le 31 décembre 2026. L'annonce d'une autorisation réglementaire, ou d'une date de clôture prévue, sans la finalisation elle-même ne compte pas. Aucune finalisation annoncée à cette date vaut Non.
État de départ vérifié
Accord de fusion signé le 18 novembre 2025. La circulaire d'information déposée auprès de la SEC (Axalta, DEFM14A, 2026) indique que les sociétés prévoient de finaliser la transaction « fin 2026 à début 2027 » ; la date limite est le 18 mai 2027, prolongeable jusqu'au 18 novembre 2027 dans certains cas. Les actionnaires d'Axalta et d'AkzoNobel ont approuvé la fusion (presse, août 2026). Les sources lues ne confirment pas que les autorisations réglementaires requises (antitrust américain au titre du HSR Act, UE, autres) aient été obtenues.
Les arguments ci-dessous ont été produits par le modèle en anglais. Ils sont affichés tels quels plutôt que traduits automatiquement, pour que rien sur cette page ne soit un texte que Asturna n'a pas réellement écrit.
Ce qui fait monter
- Shareholder approvals have already been secured and the companies have formally submitted remedies to obtain EU antitrust clearance [tier 2].
- Preparations for closing are advancing, including announcing the unified post-merger brand 'Axanzo' [tier 2].
Ce qui fait descendre
- The official proxy filing (DEFM14A) explicitly targets completion between late 2026 and early 2027, leaving a strong possibility that closing occurs in Q1 2027 [tier 1].
- Antitrust regulatory clearances in major jurisdictions, including the EU and UK, remain pending as of mid-October 2026 with only ten weeks remaining in the year [tier 2].
Ce qui ferait le plus bouger ce chiffre
The speed with which European and UK competition authorities formally issue final approvals following the submission of remedies.
Comment ce chiffre est fabriqué
| Échéance | 2026-12-31 |
| Taux de base | 40% |
| Meilleure preuve | niveau 2 · 4 article(s) utilisé(s) |
| Estimations | 30 · 35 (écart 5 pts) |
| Confiance | moyenne |
| Plafond de preuve | non déclenché |
| Révisée le | 2026-10-18 09:10 |
| Modèle | gemini-3.6-flash |
Sources consultées
Historique de la probabilité
2026-10-18 09:10 33% 26 article(s) au dossier · gemini-3.6-flash
- Ce qui fait monter. Shareholder approvals have already been secured and the companies have formally submitted remedies to obtain EU antitrust clearance [tier 2].
- Ce qui fait monter. Preparations for closing are advancing, including announcing the unified post-merger brand 'Axanzo' [tier 2].
- Ce qui fait descendre. The official proxy filing (DEFM14A) explicitly targets completion between late 2026 and early 2027, leaving a strong possibility that closing occurs in Q1 2027 [tier 1].
- Ce qui fait descendre. Antitrust regulatory clearances in major jurisdictions, including the EU and UK, remain pending as of mid-October 2026 with only ten weeks remaining in the year [tier 2].
- Ce qui ferait le plus bouger ce chiffre. The speed with which European and UK competition authorities formally issue final approvals following the submission of remedies.
2026-10-17 15:01 28% 24 article(s) au dossier · gemini-3.8-flash
- Ce qui fait monter. Shareholder approvals are already secured as of August 2026 [tier 1].
- Ce qui fait monter. Remedies have been submitted to the European Commission, and reports indicate the parties are poised to secure EU antitrust clearance [tier 2].
- Ce qui fait monter. Integration steps are moving rapidly, including unveiling the post-merger company identity 'Axanzo' with meetings scheduled for late November [tier 2, tier 4].
- Ce qui fait descendre. The official proxy statement projected closing between 'late 2026 to early 2027' with a long-stop date in May 2027, making a 2027 closing explicitly contemplated [tier 1].
- Ce qui fait descendre. Key regulatory clearances (EU, US HSR, UK CMA) have not yet been granted, with remedies only offered in mid-October and a UK probe underway since mid-September [tier 1, tier 2].
- Ce qui fait descendre. With only 75 days until 31 December 2026, satisfying regulatory remedy commitments (e.g. divestiture processes) and closing conditions for a $25 billion merger makes a completion before year-end very tight [tier 1, tier 2].
- Ce qui ferait le plus bouger ce chiffre. The timing of final, unconditional clearance decisions from the European Commission and the UK CMA, and whether remedies require an upfront buyer prior to closing.
2026-10-16 12:03 34% 21 article(s) au dossier · gemini-flash-latest
- Ce qui fait monter. Shareholder approval has already been secured by both AkzoNobel and Axalta [tier 1].
- Ce qui fait monter. Reuters reports the companies are poised to secure EU antitrust clearance following remedy offers [tier 2, article 0], supported by trade reports of divestment proposals [tier 4, article 2].
- Ce qui fait monter. Post-merger integration steps, such as establishing the new combined name Axanzo, are actively progressing [tier 4, article 3].
- Ce qui fait descendre. The official proxy statement projected closing between 'late 2026 to early 2027' with long-stop dates well into 2027, making a slip past December 31 very plausible within their stated plan [tier 1].
- Ce qui fait descendre. Only 2.5 months remain before the deadline, while the UK Competition and Markets Authority only recently initiated its probe in mid-September 2026 [tier 2, article 1].
- Ce qui fait descendre. US antitrust clearance and formal EU approval have not yet been granted [tier 1], and finalizing divestitures or remedies typically requires additional weeks before closing can legally occur.
- Ce qui ferait le plus bouger ce chiffre. Whether the UK CMA and EU regulators grant final clearance without requiring Phase 2 investigations or protracted remedy negotiations before mid-December 2026.
2026-10-15 16:44 45% 10 article(s) au dossier · openai/gpt-oss-120b (Groq)
- Ce qui fait monter. EU antitrust approval appears likely according to Reuters report, removing a major hurdle [2]
- Ce qui fait descendre. No confirmed regulatory clearances yet; proxy expects completion late 2026 to early 2027, so could slip past the deadline [hand‑verified tier 1]
- Ce qui fait descendre. Tier‑4 name announcements provide no evidence of closing
- Ce qui ferait le plus bouger ce chiffre. Whether the EU, US and other antitrust authorities grant clearance before 31 Dec 2026